NLS Agreement

Swedish biotech company Akiram Therapeutics has signed an agreement with ITM Isotope Technologies Munich to supply non-carrier-added lutetium-177 for the clinical development of AKIR001.

SynAct Pharma has signed a term sheet with Brazilian pharmaceutical company Hipolabor to co-develop and commercialize resomelagon for dengue and other viral infections in Brazil.

Zealand Pharma has entered into a royalty purchase and sale agreement with Royalty Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.

Swedish Orphan Biovitrum and Innate Pharma have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL).

AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.

Prolight Diagnostics has announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions.